Evommune, Inc. Reports Q2 2026 Financial Results

What Happened
Evommune, Inc. announced on August 6, 2026 that it issued a press release providing a business update and reporting its financial results for the quarter ended June 30, 2026. The press release was furnished with the Form 8‑K (Item 2.02) as Exhibit 99.1 and is incorporated by reference into the filing.

Key Details

• Filing date: August 6, 2026 (Form 8‑K).
• Period covered: Quarter ended June 30, 2026 (Q2 2026).
• Disclosure: Company furnished a press release with business update and financial results (Exhibit 99.1).
• Report signed on the company’s behalf by Luis Peña, President and Chief Executive Officer.

Why It Matters
This 8‑K signals that Evommune has released its quarterly earnings and an operational update; those details (revenue, expenses, net income/loss, guidance or cash position) will be in the attached press release. Investors should review Exhibit 99.1 for the specific financial figures and any management commentary, and watch for subsequent SEC filings (such as a Form 10‑Q) for the full, audited/regular quarterly disclosures.